Beyond the 5-year milestone: Long-term survivorship of melanoma patients treated off-trial with anti-PD-1 Journal Article

   


Authors: Loo, K.; Kalvin, H. L.; Panageas, K. S.; Callahan, M. K.; Chapman, P. B.; Momtaz, P.; Shoushtari, A. N.; Wolchok, J. D.; Postow, M. A.; Warner, A. B.
Article Title: Beyond the 5-year milestone: Long-term survivorship of melanoma patients treated off-trial with anti-PD-1
Abstract: Little is known about the long-term outcomes of anti-PD-1 treated patients with melanoma beyond 5 years, especially for patients treated off clinical trials. This retrospective cohort study includes patients with unresectable stage III/IV nonuveal melanoma treated with anti-PD-1 off-trial at Memorial Sloan Kettering Cancer Center between 2014 and 2017 who survived at least 5 years following their first anti-PD-1 dose (N = 139). We characterized overall survival (OS), melanoma-specific survival (MSS) estimates, treatment-free survival rates, and subsequent treatment courses. Median follow-up among 5-plus year survivors (N = 125) was 78.4 months (range 60.0–96.3). OS at year 7 (2 years post 5-year landmark) was 90.1% (95% CI: 83.0%–94.3%). Fourteen deaths occurred, seven due to melanoma. MSS at year 7 (2 years post 5-year landmark) was 95.0% (95% CI: 33.5%–95.2%). In patients who completed anti-PD-1 based therapy and did not require subsequent treatment by 5 years (N = 80), the probability of not requiring additional treatment for an additional 2 years was 95.7% (95% CI: 91.0%–100%). Patients treated with anti-PD-1 regimens off clinical trials who survive at least 5 years from initial anti-PD-1 treatment can be reassured of their excellent long-term prognosis, particularly if they did not require additional melanoma treatment during the first 5 years. © 2023 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Keywords: adult; cancer survival; aged; survival rate; treatment failure; retrospective studies; major clinical study; overall survival; drug withdrawal; unspecified side effect; cancer patient; cancer staging; follow up; clinical practice; ipilimumab; melanoma; skin neoplasms; cohort analysis; retrospective study; cancer mortality; cancer survivor; skin tumor; population research; immunotherapy; cancer specific survival; brain metastasis; survivorship; inoperable cancer; medical history; clinical outcome; clinician; long-term survivorship; cancer prognosis; nivolumab; humans; human; male; female; article; anti-pd-1; pembrolizumab; clinical trial protocol; treatment free survival; melanoma, cutaneous malignant; off-trial
Journal Title: Pigment Cell & Melanoma Research
Volume: 36
Issue: 3-4
ISSN: 1755-1471
Publisher: Wiley Blackwell  
Date Published: 2023-05-01
Start Page: 314
End Page: 320
Language: English
DOI: 10.1111/pcmr.13083
PUBMED: 37039320
PROVIDER: scopus
PMCID: PMC11072376
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85152459860&doi=10.1111%2fpcmr.13083&partnerID=40&md5=fa2876de02a4bd97a5a707d35fb9b511
Notes: Article-- MSK Cancer Center Support Grant (P30 CA008748) acknowledged in PubMed and PDF -- MSK corresponding author is Allison Betof Warner -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Jedd D Wolchok
    905 Wolchok
  2. Michael Andrew Postow
    361 Postow
  3. Paul Chapman
    326 Chapman
  4. Margaret Kathleen Callahan
    197 Callahan
  5. Katherine S Panageas
    512 Panageas
  6. Alexander Noor Shoushtari
    244 Shoushtari
  7. Parisa Momtaz
    54 Momtaz
  8. Allison Betof Warner
    76 Betof Warner
  9. Kimberly Leticia Loo
    6 Loo
  10. Hannah Kalvin
    30 Kalvin
Related MSK Work